Caribou Biosciences (CRBU) Net Income towards Common Stockholders (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$28.1 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 34.68% year-over-year to -$28.1 million in Q1 2026; TTM through Mar 2026 was -$137.2 million, a 36.51% increase from a year earlier, with the FY2025 full-year figure at -$148.1 million, up 0.66% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$28.1 million, up from -$28.9 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for CRBU reached as high as -$22.7 million in Q1 2022 and fell as low as -$87.4 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged -$46.9 million across 5 years, with a median of -$40.3 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders sank 431.74% in 2022 and jumped 57.42% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$31.1 million in 2022, then retreated by 20.89% to -$37.6 million in 2023, then decreased by 7.3% to -$40.3 million in 2024, then rose by 28.28% to -$28.9 million in 2025, then advanced by 2.77% to -$28.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$28.1 million in Q1 2026, -$28.9 million in Q4 2025, and -$32.4 million in Q3 2025.